Femoral Neck System and Cement Augmentation for Temporizing a Pathologic Hip Fracture in Osteosarcoma: A Case Report.

JBJS Case ConnectSep 24, 2026 (epub)
Case ReportOncology (Medical)Orthopedic Surgery

Christopher M Liu, Kevin Y Zhu, Phoebe Stark et al.

✦ AI-curated · Sources linked

Case in brief

A 17-year-old boy with primary osteosarcoma presented with a pathologic hip fracture. He underwent cement-augmented internal fixation using a femoral neck system, which facilitated pain management and allowed for the completion of neoadjuvant chemotherapy and necessary diagnostic evaluations prior to definitive surgical intervention. At three years post-surgery, there were no complications or local recurrences.

Diagnostic / clinical pearl

Cement-augmented internal fixation can be an effective temporizing measure for pathologic hip fractures in osteosarcoma, enabling further treatment planning.

Why it matters

This case highlights the importance of balancing immediate fracture management with the need for comprehensive oncological treatment in patients with bone tumors.

Source

PubMed · PMID 42809649

Published in JBJS Case Connect. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.